Takeda Pharmaceutical Co. and Pfizer Japan Inc. announced on June 18 that they have concluded an agreement in which Takeda will cease distribution of 13 of the 15 Pfizer products that it previously procured from Wyeth K.K. and currently distributes under an exclusive distribution agreement with Pfizer.
Pfizer, the manufacturer of the products, will begin selling them after Dec. 31, when the agreement takes effect.
In addition, Takeda will continue to distribute the pneumococcus vaccine Prevenar for infants and young children and the hemophilia B drug BeneFIX after January 2013.
The 13 products it will stop distributing are Isovorin; the active folate Artane, a treatment for Parkinson's syndrome; Amoxan, a treatment for depression; Torisel; the anticancer agent Napageln; the transdermal anti-inflammatory drug Photofrin; Premarin, a treatment for photodynamic therapy; the conjugated estrogens Mylotarg; the anticancer agent Minomycin; the antibiotic Methotrexate; the folate metabolism blocker Rheumatrex; Leucovorin, a treatment for rhematoid arthritis; and the antifolate metabolism blocker Wypax, a minor tranquilizer.
- « Prev
- Next »